CFTR correctors, a therapy for cystic fibrosis targeted at specific mutations

Cystic fibrosis is a common inherited condition, particularly affecting people from a northern European background.   It's caused by various mutations of the Cystic Fibrosis Transmembrane Conductance Regulator gene, shortened to "CFTR".  A new Cochrane Review from August 2018 examines a class of drug that aims to correct the basic defect for people with CF with a specific mutation, and we asked lead author, Kev in Southern from the University of Liverpool in the UK, to tell us what they found.
Source: Podcasts from The Cochrane Library - Category: General Medicine Authors: Source Type: podcasts